Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 03 May 2017 Planned number of patients changed from 440 to 300.